Tool to estimate burden of maternal syphilis and adverse outcomes
This tool is intended for use by countries to estimate the burden of syphilis in pregnancy and associated adverse outcomes using readily available data. This simple tool can be used at a national or a subnational level. The methodologies used in the tools have been reviewed and approved by the Child Health Epidemiology Research Group and used for the recent global estimates. An accompanying set of instructions is available to guide the user through the estimation process.
Monitoring the emergence and spread of antimicrobial resistance in gonorrhoea
The rapidly changing antimicrobial
susceptibility of Neisseria gonorrhoeae has
created an important public health problem.
The Gonococcal Antimicrobial Surveillance Programme (GASP) has documented the emergence and spread of antimicrobial resistance in gonorrhoea since 1992 and has provided evidence to inform national, regional, and global treatment guidelines. The GASP is a worldwide laboratory network that is coordinated by focal points and regional coordinating centres.
Syphilis affects large numbers of pregnant women worldwide, causing serious health problems and even death to their babies. One study estimates the percentage of pregnant women tested for syphilis and adequately treated, ranges from 30% for Africa and the Mediterranean region to 70% for Europe. Another study suggests that, unless testing and treatment of syphilis in pregnancy are universally available, over half of pregnancies in women with syphilis will result in an adverse outcome.
For the first time, country-level STI data are available through the WHO Global Health Observatory. This data are reported by countries to WHO. Below are the currently available indicators.